Alteogen announced a new option and license agreement with Novartis for the development and commercialization of multiple SC products using its proprietary Hybrozyme platform.

Alteogen is a leading biopharmaceutical company with a robust pipeline of next-generation biologics featuring enhanced efficacy, enabled by its proprietary platform technologies. Founded in 2008, the company is listed on the KOSDAQ stock exchange (KRX:196170). Alteogen’s most distinguished platform, Hybrozyme™, is a novel human hyaluronidase technology that enhances the absorption of biologic drugs administered via subcutaneous injection. This proprietary hyaluronidase demonstrates improved enzymatic activity and thermal stability compared to existing alternatives. Another key innovation, NexP™ fusion technology, is designed to extend the half-life of therapeutic proteins and peptides in the human body. It is currently applied to the development of long-acting biologics, including human growth hormone, exenatide (for diabetes), and Factor VIIa (for hemophilia). The company’s proprietary antibody-drug conjugate platform, NexMab™ ADC technology, enables targeted cancer therapies with improved efficacy and reduced side effects. Using this platform, Alteogen is developing ADC therapeutics for breast, gastric, and ovarian cancers. With extensive expertise and experience, Alteogen has also established its own high-expression cell lines, efficient upstream and downstream processes, and optimized analytical methods to support the development of monoclonal antibody biosimilars.

Founded 2008